Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

WITH the price of Mounjaro set to rise and concerns about long-term affordability and access, many may be looking to turn to alternative treatments, like Wegovy. But how do the two weight loss ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Mounjaro, one of the UK’s most popular weight-loss jabs, is set to become more expensive for private patients after Eli Lilly ...

Copycat weight loss drugs on the rise Weight loss hacks promising quick fixes for slimming have a long history. But they have risen to a whole new level since Ozempic and Wegovy became popular.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

By Nqobile Dludla and Siyanda Mthethwa JOHANNESBURG (Reuters) -Danish drugmaker Novo Nordisk introduced its weight-loss drug ...

Wegovy mimics a naturally occurring hormone, GLP-1, that regulates appetite and blood sugar. Combined with movement and nutritious meals, studies show Wegovy can support sustained weight loss.

At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight-loss jab, through private prescriptions ...

When the trial concluded, individuals who took Zepbound lost roughly 20% of their body weight on average, compared with almost 14% loss for those who took Wegovy.

Wegovy, or semaglutide, is the newest weight loss medication to receive regulatory approval. Wegovy was recently approved, on 4 June 2021, by the US Food and Drug Administration (FDA) for the ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...